Answers are grounded in this paper and cite their sources.
Integrated proteomic analysis reveals ALDH1A1's role as an oncogenic driver in hepatocellular carcinoma, suggesting therapeutic targets.
BACKGROUND/AIM: Although aldehyde dehydrogenases 1 family member A1 (ALDH1A1) has been extensively studied in cancer, its role in hepatocellular carcinoma (HCC) remains poorly understood. This study was designed to characterize the expression pattern and functional roles of ALDH1A1 in HCC, and to further investigate its underlying molecular mechanisms using integrated proteomic analysis. MATERIALS AND METHODS: . Quantitative proteomic and phosphoproteomic profiling were conducted by liquid chromatography-tandem mass spectrometry, with comprehensive analyses and key findings validated by experiments. RESULTS: activating Rho family small GTPase. ALDH1A1 also significantly upregulated mTOR phosphorylation. CONCLUSION: ALDH1A1 acts as an oncogenic driver and regulatory hub in HCC.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: